Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.38 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.38 |
| ▸ | SLC9A1 | P19634 | 6/20 | 0.35 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22085849 | 0.96 | GRM2 (0.37) | CSNK2A2CSNK2BCSNK2A1CSNK2A3GRM2 | |
| SCHEMBL30159300 | 0.81 | HCAR3 (0.39) | CSNK2A2CSNK2BCSNK2A1CSNK2A3GRM2 | |
| SCHEMBL22032162 | 0.79 | GRM2 (0.50) | CSNK2A2CSNK2BCSNK2A1CSNK2A3GRM2 | |
| SCHEMBL28855453 | 0.78 | CCNC (0.39) | GRM2HCAR3 | |
| SCHEMBL29901087 | 0.78 | CCNC (0.39) | GRM2HCAR3 | |
| SCHEMBL22085615 | 0.75 | RAB9A (0.35) | HCAR3 | |
| SCHEMBL24296919 | 0.75 | GRM2 (0.49) | CSNK2A2CSNK2BCSNK2A1CSNK2A3GRM2 | |
| SCHEMBL29901109 | 0.74 | GRM2 (0.48) | CSNK2A2CSNK2BCSNK2A1CSNK2A3GRM2 | |
| SCHEMBL28855359 | 0.74 | GRM2 (0.48) | CSNK2A2CSNK2BCSNK2A1CSNK2A3GRM2 | |
| SCHEMBL22084319 | 0.73 | HCAR3 (0.35) | HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518763-B2 | Macrocyclic compound and use thereof | SCOHIA PHARMA, INC. (JP) | 2022-12-06 | — | — | US | disclosed |
| US-20220119391-A1 | MACROCYCLIC COMPOUND AND USE THEREOF | SCOHIA PHARMA, INC. (JP) | 2022-04-21 | — | — | US | disclosed |
| EP-3890738-A1 | MACROCYCLIC COMPOUND AND USE THEREOF | Scohia Pharma, Inc. (JP) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020116660-A1 | MACROCYCLIC COMPOUND AND USE THEREOF | SCOHIA PHARMA, INC. (JP) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020116660-A1 | MACROCYCLIC COMPOUND AND USE THEREOF | SCOHIA PHARMA, INC. (JP) | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518763-B2 | Macrocyclic compound and use thereof | TFAM, KEAP1, FASTKD1 | CSNK2A2 2957/4885CSNK2B 3291/4885CSNK2A1 2919/4885 |
| US-20220119391-A1 | MACROCYCLIC COMPOUND AND USE THEREOF | TFAM, KEAP1, CKMT1A; CKMT1B | CSNK2A2 2825/4885CSNK2B 3130/4885CSNK2A1 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.